
Evidence-Based Oncology Looks at How the Cost of Cancer Care Affects Treatment
At what point does the cost of cancer therapy affect the results? The current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, takes on one of today’s biggest treatment challenges: the eye-popping prices of today’s new therapies can erect barriers to care before it begins.
FOR IMMEDIATE RELEASEAugust 31, 2016
PLAINSBORO, N.J.—It’s the paradox that confronts providers and patients at every level of cancer care: there are more life-saving treatments than ever, yet cost puts so many of them out of reach.
So common, and so troubling is this problem that researchers now refer to “financial toxicity” as the effect that cost burdens have on cancer patients and families alike. Questions, and possible solutions, to this problem are examined in the current issue of
As EBO Editor-in-Chief
The issue features data prepared by the
Young adult cancer survivors are especially hard hit by the cost of cancer treatment, according to authors from
Jeffrey W. Chell, MD, writes of the need to remove barriers to bone marrow and cord blood
Other topics covered in the issue include solutions for reducing patient cost sharing, and a discussion of whether the cost sharing burden affects
About the Journals and AJMC.com
The American Journal of Managed Care is the leading peer-reviewed journal dedicated to issues in managed care.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.